Therapeutic Asset Ratings
6,371 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Ipilimumab
Metastatic Malignant Neoplasm
Federation Francophone de Cancerologie Digestive
P3
BB
(66)
LECANEMAB
Familial Alzheimer Disease
Washington University School of Medicine
P3
BB
(66)
Nivolumab
Skin Cancer
7 Hills Pharma, LLC
P3
BB
(66)
PANITUMUMAB
Colon Adenocarcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(66)
PANITUMUMAB
RAS Wild Type
Emory University
P3
BB
(66)
Pembrolizumab
Biliary Tract Cancer
Merck Sharp & Dohme LLC
P3
BB
(66)
Pembrolizumab
Urinary Bladder Carcinoma
Essen Biotech
P3
BB
(66)
Pembrolizumab
Head And Neck Cancer
Thomas Jefferson University
P3
BB
(66)
Pembrolizumab
Gastric Neoplasm
Merck Sharp & Dohme LLC
P3
BB
(66)
Pembrolizumab
Triple-Negative Breast Carcinoma
M.D. Anderson Cancer Center
P3
BB
(66)
Relatlimab
Cutaneous Melanoma
University Health Network, Toronto
P3
BB
(66)
Serplulimab
Malignant Pancreatic Neoplasm
Zhejiang Cancer Hospital
P3
BB
(66)
Surovatamig
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AstraZeneca
P3
BB
(66)
Tifcemalimab
Small Cell Lung Carcinoma
Sichuan University
P3
BB
(66)
Toripalimab
Extranodal Nasal NK/T Cell Lymphoma
Beijing Tongren Hospital
P3
BB
(66)
Toripalimab
Toripalimab
Fudan University
P3
BB
(66)
TRASTUZUMAB
Colon Adenocarcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(66)
TRASTUZUMAB
Estrogen-Receptor Positive Breast Cancer
Dana-Farber Cancer Institute
P3
BB
(66)
Vibostolimab
Non-Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
P3
BB
(66)
Atezolizumab
Urinary Bladder Cancer
National Cancer Institute (NCI)
P2
BB
(66)
Balstilimab
Colorectal Adenocarcinoma
City of Hope Medical Center
P2
BB
(66)
Botensilimab
Colorectal Adenocarcinoma
City of Hope Medical Center
P2
BB
(66)
Durvalumab
Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
P2
BB
(66)
Durvalumab
Estrogen-Receptor Positive Breast Cancer
National Taiwan University Hospital
P2
BB
(66)
Durvalumab
Malignant Pancreatic Neoplasm
Jonsson Comprehensive Cancer Center
P2
BB
(66)
Showing 276 to 300 of 6,371 assets
Previous
Page 12 of 255
Next